Want to see GEHC full AI Analyst Report?
GEHC Stock Chart & Stats
$60.58
-$1.38(-2.22%)
At close: 4:00 PM EDT
$60.58
-$1.38(-2.22%)
Day’s Range― - ―
52-Week Range$58.75 - $89.77
Previous CloseN/A
Volume9.13M
Average Volume (3M)4.95M
Market Cap
$32.81B
Enterprise Value$37.74K
Total Cash (Recent Filing)$2.10B
Total Debt (Recent Filing)$10.09B
Price to Earnings (P/E)21.4
Beta1.27
Next Earnings
Nov 04, 2026EPS Estimate
1.2Next Dividend Ex-DateN/A
Dividend Yield0.19%
Share Statistics
EPS (TTM)3.48
Shares Outstanding451,686,250
10 Day Avg. Volume6,117,812
30 Day Avg. Volume4,946,626
Financial Highlights & Ratios
PEG Ratio4.14
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$79.07Price Target Upside30.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)4.93
Revenue Forecast (FY)$21.72B
Bulls Say, Bears Say
Bulls Say
Backlog And Recurring Service GrowthStrong orders and a record backlog support multi-period revenue visibility, while faster service growth adds recurring, higher-frequency revenue from GEHC’s installed equipment base.
Pharmaceutical Diagnostics GrowthPDx combines strong current growth with high profitability and an expanding radiopharmaceutical opportunity. Flyrcado’s customer ramp could add a durable growth engine as adoption broadens.
Improving Balance Sheet ResilienceLower leverage and a larger equity base improve financial resilience and flexibility. Although debt remains meaningful, the direction of balance-sheet repair supports investment in products and operations.
Bears Say
Patient Care Solutions WeaknessPCS represents a material execution and portfolio risk because supply and fulfillment problems are already producing negative EBIT. A strategic review signals that recovery or restructuring may require time and resources.
Margin Pressure From InflationPersistent component, memory, oil and freight costs can limit margin expansion even when revenue grows. Pricing and cost actions may offset the pressure, but sustained inflation could weaken earnings quality.
Weaker Free Cash Flow GenerationThe decline in free cash flow reduces internally generated funding for debt reduction, innovation and capital returns. Q2’s refund distortion also highlights volatility and makes cash conversion less predictable.
GE Healthcare Technologies Inc News
GEHC FAQ
What was Ge Healthcare Technologies Inc.’s price range in the past 12 months?
Ge Healthcare Technologies Inc. lowest stock price was $58.75 and its highest was $89.77 in the past 12 months.
What is Ge Healthcare Technologies Inc.’s market cap?
Ge Healthcare Technologies Inc.’s market cap is $32.81B.
When is Ge Healthcare Technologies Inc.’s upcoming earnings report date?
Ge Healthcare Technologies Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 76 days.
How were Ge Healthcare Technologies Inc.’s earnings last quarter?
Ge Healthcare Technologies Inc. released its earnings results on Jul 29, 2026. The company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.036 by $0.094.
Is Ge Healthcare Technologies Inc. overvalued?
According to Wall Street analysts Ge Healthcare Technologies Inc.’s price is currently Undervalued.
Does Ge Healthcare Technologies Inc. pay dividends?
Ge Healthcare Technologies Inc. pays a Quarterly dividend of $0.035 which represents an annual dividend yield of 0.19%. See more information on Ge Healthcare Technologies Inc. dividends here
What is Ge Healthcare Technologies Inc.’s EPS estimate?
Ge Healthcare Technologies Inc.’s EPS estimate is 1.2.
How many shares outstanding does Ge Healthcare Technologies Inc. have?
Ge Healthcare Technologies Inc. has 451,686,250 shares outstanding.
What happened to Ge Healthcare Technologies Inc.’s price movement after its last earnings report?
Ge Healthcare Technologies Inc. reported an EPS of $1.13 in its last earnings report, beating expectations of $1.036. Following the earnings report the stock price went up 12.151%.
Which hedge fund is a major shareholder of Ge Healthcare Technologies Inc.?
Currently, no hedge funds are holding shares in GEHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GE Healthcare Technologies Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$79.07 (30.52% Upside)
$79.07 (30.52% Upside)
Blogger Sentiment
Bullish
GEHC Sentiment 88%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 723.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $641.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.90%
12-Months-Change
Fundamentals
Return on Equity
0.19%
Trailing 12-Months
Asset Growth
4.92%
Trailing 12-Months
Company Description
Ge Healthcare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
GEHC Company Deck
GEHC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed strong commercial momentum: record orders, backlog, solid revenue growth, PDx outperformance, AIS margin expansion, and progress on new AI-enabled products and Flyrcado ramp. Offsetting these positives were meaningful near-term challenges in Patient Care Solutions (13.5% organic decline and negative segment EBIT), inflationary headwinds (memory, oil, freight), and cash volatility driven by tariff refunds. Management maintained full-year guidance and reiterated medium-term targets, expressing confidence in recovery actions and the innovation pipeline.View all GEHC earnings summariesGEHC Revenue Breakdown
44.82% Imaging
25.96% AVS
14.96% PCS
14.06% PDx
0.19% Other

GEHC Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$79.07
▲(30.52% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Veeva Systems
―
Healthequity
―
Doximity
―
Tempus AI, Inc. Class A
―
Hinge Health, Inc. Class A
―
Ownership Overview
0.30% Insiders
33.57% Mutual Funds
27.66% Other Institutional Investors
7.07% Public Companies and Individual Investors










